CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

We recently published an article titled Why Traders Flocked to These 10 Stocks on Monday. In this article, we are going to ...

CG Oncology shares rose Monday after the company shared positive data from a study of its bladder-cancer treatment. The stock gained 39% to $31.10 in premarket trading.

Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer ...

Shares of CG Oncology Inc. gained 25% April 28 on the back of phase III data presented at the American Urological Association meeting over the weekend showing its cretostimogene grenadenorepvec ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

Bladder cancer is the sixth most common form of cancer ... been established by the FDA or any other health authority. About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical ...

Scotiabank initiated coverage of CG Oncology (CGON) with a Sector Perform rating and $23 price target The company is developing a novel ...

BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.

CG Oncology’s primary focus has been on advancing ... Targeted approach: The specificity of oncolytic viruses in targeting cancer cells while sparing healthy tissue could potentially result ...